Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony W Tolcher

Showing results (61-70 of 123) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2007
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1Anthony W Tolcher, Monica Mita, Neal J Meropol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumorsAlain C Mita, Louis J Denis, Eric K Rowinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumorsAlejandro D Ricart, Jordan D Berlin, Kyriakos P Papadopoulos, et al.
Cancer Chemotherapy and Pharmacology|November 25, 2014
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myelomaAnthony W Tolcher, Amita Patnaik, Kyriakos P Papadopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1Anthony W Tolcher, John Sarantopoulos, Amita Patnaik, et al.
Investigational New Drugs|February 3, 2022
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignanciesJordan Berlin, Anthony W Tolcher, Cliff Ding, et al.
Cancer Chemotherapy and Pharmacology|March 11, 2017
A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumorsAnthony W Tolcher, Jordan D Berlin, Jan Cosaert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignanciesMitchell A Garrison, Lisa A Hammond, Charles E Geyer, et al.
Investigational New Drugs|March 20, 2020
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFRJames M Cleary, Emiliano Calvo, Victor Moreno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2014
Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumorsToshio Shimizu, Patricia M LoRusso, Kyri P Papadopoulos, et al.
Pageof 13

Showing results (61-70 of 123) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2007
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1Anthony W Tolcher, Monica Mita, Neal J Meropol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumorsAlain C Mita, Louis J Denis, Eric K Rowinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumorsAlejandro D Ricart, Jordan D Berlin, Kyriakos P Papadopoulos, et al.
Cancer Chemotherapy and Pharmacology|November 25, 2014
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myelomaAnthony W Tolcher, Amita Patnaik, Kyriakos P Papadopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1Anthony W Tolcher, John Sarantopoulos, Amita Patnaik, et al.
Investigational New Drugs|February 3, 2022
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignanciesJordan Berlin, Anthony W Tolcher, Cliff Ding, et al.
Cancer Chemotherapy and Pharmacology|March 11, 2017
A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumorsAnthony W Tolcher, Jordan D Berlin, Jan Cosaert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignanciesMitchell A Garrison, Lisa A Hammond, Charles E Geyer, et al.
Investigational New Drugs|March 20, 2020
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFRJames M Cleary, Emiliano Calvo, Victor Moreno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2014
Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumorsToshio Shimizu, Patricia M LoRusso, Kyri P Papadopoulos, et al.
Pageof 13